Adherex Announces Presentations on ADH-1 'Exherin'TM'' at American Association of Cancer Research.RESEARCH TRIANGLE PARK Research Triangle Park, research, business, medical, and educational complex situated in central North Carolina. It has an area of 6,900 acres (2,795 hectares) and is 8 × 2 mi (13 × 3 km) in size. Named for the triangle formed by Duke Univ. , N.C. -- Adherex Technologies Inc. (AMEX AMEX See: American Stock Exchange :ADH ADH: see antidiuretic hormone. )(TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :AHX AHX American History X (movie) AHX Abyss' Highest eXperience ), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that the Company will give two poster presentations on its lead biotechnology compound, ADH-1 (Exherin(TM)), at the 96th Annual Meeting of the American Association of Cancer Research in Anaheim, CA, April 16-20, 2005: -"Further observations concerning the effects of N-cadherin antagonist Exherin(TM) (ADH-1) on endothelial cells Endothelial cells The cells lining the inner walls of the blood vessels. Mentioned in: Von Willebrand Disease and tumor blood vessels" by Normand Lavoie, Emmanualle Devamy, Eugene A. Lepekhin, and Orest Blaschuk - Sunday, April 17, 2005 at 1 p.m. -"Preclinical safety and pharmacokinetic evaluation of Exherin(TM) (ADH-1) in Beagle dogs" by Jan K. Losos, Robin J. Norris, William P. Peters, Eugene A. Lepekhin and Brian E. Huber - Tuesday, April 19, 2005 at 8 a.m. Following the meeting, Adherex will make the posters available on its website at www.adherex.com. About Adherex Technologies Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have four products in the clinical stage of development including ADH-1 (Exherin(TM)) and sodium thiosulfate (STS (Synchronous Transport Signal) The electrical equivalent of the SONET optical signal. In SDH, the European counterpart of SONET, STS is known as STM (Synchronous Transport Module). ). ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex is emerging as a pioneering oncology company. For more information, please visit our website at www.adherex.com. Adherex Technologies Inc. (TSX:AHX) (AMEX:ADH) |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion